首页> 外文期刊>Biochemistry >Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025
【24h】

Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025

机译:环孢菌素A类似物Debio 025的非免疫抑制特性的结构基础

获取原文
获取原文并翻译 | 示例
       

摘要

Debio 025 is a cyclosporin A (CsA) analogue that interferes strongly with the hepatitis C viral life cycle. Compared to CsA, Debio 025 has an additional methyl group at position 3 of the cyclic undecapeptide and an N-ethylvaline instead of an N-methylleucine at position 4. Unlike CsA, Debio 025 lacks immuno- suppressive activity in vitro and in vivo. We show here that, in vitro, the cyclophilin A (CypA)-Debio 025 complex cannot interact any longer with calcineurin (CaN), a determinant for the immunosuppressive activity of CsA.We further use NMR spectroscopy to investigate at the molecular level the interaction of Debio 025 with CypA and thereby understand the basis for this loss of CaN interaction. NMR data and molecular modeling indicate that Debio 025 optimally interacts with CypA, which underlies the anti-HCV properties of Debio 025. However, the interaction between CaN and the CypA-Debio 025 complex is impeded by sterical hindrance of the CaN with the side chain of its Val4 residue. This is in sharp cont ast with the case for the CypA-CsA-CaN ternary complex, where the Leu4 side chain can enter a hydrophobic cavity at the CaN interface. The structure of the CypA-Debio 025 complex thus provides a rational explanation for the non- immunosuppressive character of Debio 025.rncycle. Compared to CsA, Debio 025 has an additional methyl group at position 3 of the cyclic undecapeptidernand an N-ethylvaline instead of an N-methylleucine at position 4. Unlike CsA, Debio 025 lacks immuno-rnsuppressive activity in vitro and in vivo. We show here that, in vitro, the cyclophilin A (CypA)-Debio 025rncomplex cannot interact any longer with calcineurin (CaN), a determinant for the immunosuppressive activityrnof CsA.We further use NMR spectroscopy to investigate at the molecular level the interaction of Debio 025rnwith CypA and thereby understand the basis for this loss of CaN interaction. NMR data and molecularrnmodeling indicate that Debio 025 optimally interacts with CypA, which underlies the anti-HCV properties ofrnDebio 025. However, the interaction between CaN and the CypA-Debio 025 complex is impeded by stericalrnhindrance of the CaN with the side chain of its Val4 residue. This is in sharp contrast with the case for thernCypA-CsA-CaN ternary complex, where the Leu4 side chain can enter a hydrophobic cavity at the CaNrninterface. The structure of the CypA-Debio 025 complex thus provides a rational explanation for the non-rnimmunosuppressive character of Debio 025.
机译:Debio 025是一种环孢菌素A(CsA)类似物,可强烈干扰丙型肝炎病毒的生命周期。与CsA相比,Debio 025在环状十一肽的第3位具有一个额外的甲基,在第4位具有N-乙基缬氨酸而不是N-甲基亮氨酸。与CsA不同,Debio 025在体外和体内均缺乏免疫抑制活性。我们在这里显示出亲环蛋白A(CypA)-Debio 025复合物不能再与钙调神经磷酸酶(CaN)相互作用,而钙调神经磷酸酶(CaN)是CsA免疫抑制活性的决定因素。我们进一步使用NMR光谱在分子水平研究相互作用Debio 025与CypA的结合,从而了解这种CaN相互作用丧失的基础。 NMR数据和分子模型表明,Debio 025与CypA最佳相互作用,这是Debio 025的抗HCV特性的基础。但是,CaN和CypA-Debio 025复合物之间的相互作用受到CaN与侧链的空间位阻的阻碍。 Val4残基。与CypA-CsA-CaN三元复合物的情况形成鲜明对比,其中Leu4侧链可以在CaN界面处进入疏水腔。因此,CypA-Debio 025复合物的结构为Debio 025环的非免疫抑制特性提供了合理的解释。与CsA相比,Debio 025在环状未去肽链的3位上有一个额外的甲基,在4位是N-乙基缬氨酸而不是N-甲基亮氨酸。与CsA不同,Debio 025在体内外都缺乏免疫抑制活性。我们在这里显示出亲环蛋白A(CypA)-Debio 025rn复合物不能再与钙调神经磷酸酶(CaN)相互作用,而钙调神经磷酸酶是决定CsA免疫抑制活性的因素。我们进一步使用NMR光谱在分子水平上研究Debio的相互作用025rn与CypA结合,从而了解这种CaN相互作用丧失的基础。 NMR数据和分子模型表明,Debio 025与CypA最佳相互作用,这是rnDebio 025的抗HCV特性的基础。但是,CaN和CypA-Debio 025复合物之间的相互作用受到CaN及其Val4侧链的空间位阻的阻碍。残留物。这与rnCypA-CsA-CaN三元复合物的情况形成鲜明对比,后者的Leu4侧链可以在CaNrn接口处进入疏水腔。因此,CypA-Debio 025复合物的结构为Debio 025的非免疫抑制特性提供了合理的解释。

著录项

  • 来源
    《Biochemistry》 |2010年第22期|p.4679-4686|共8页
  • 作者单位

    Structural and Functional Glycobiology Unit, UMR8576 CNRS-Universite des Sciences et Technologies de Lille, Lille, France,and Department of Biochemistry and Molecular Biology, Beijing Normal University, Beijing 100875, ChinaDebiopharm, Lausanne CP211, Switzerland,) ULP, Laboratoire d’Infochimie, UMR 7177, Strasbourg, France, and Department of Biochemistry and Molecular Biology, Beijing Normal University, Beijing 100875, ChinaStructural and Functional Glycobiology Unit, UMR8576 CNRS-Universite des Sciences et Technologies de Lille, Lille, France,§Debiopharm, Lausanne CP211, Switzerland,) ULP, Laboratoire d’Infochimie, UMR 7177, Strasbourg, France, and^Department of Biochemistry and Molecular Biology, Beijing Normal University, Beijing 100875, China#These authors contributed equally to this work;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 13:37:23

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号